Cardiac Atrophy and Heart Failure In Cancer

Overview

Journal Card Fail Rev

Date 2017 Aug 9

PMID 28785478

Citations 18

Authors

Mark Sweeney

Angela Yiu

Alexander R Lyon

Affiliations

Soon will be listed here.

Abstract

Functional changes in the heart in patients with cancer can be a result of both the disease itself and various cancer therapies, and limiting cardiac damage has become an increasingly important issue as survival rates in patients with cancer have improved. Processes involved in cancer-induced cardiac atrophy may include cardiomyocyte atrophy and apoptosis, decreased protein synthesis, increased autophagy and proteolysis via the ubiquitin-proteosome system. Further to direct effects of malignancy on the heart, several chemotherapeutic agents are known to affect the myocardium, in particular the anthracyclines. The aim of this report is to review the effects of cancer and cancer treatment on the heart and what is known about the underlying mechanisms. Furthermore, clinical strategies to limit and treat cancer-associated cardiac atrophy are discussed, emphasising the benefit of a multidisciplinary approach by cardiologists and oncologists to optimise models of care to improve outcomes for patients with cancer.

Citing Articles

Cardiotoxicity Associated With a Low Doses of 5-FU Promotes Morphoquantitative Changes in the Intrinsic Cardiac Nervous System.

da Costa Salomao K, da Silva M, Fabiano L, Freitas P, Neves C, Borges S Cardiovasc Toxicol. 2025; 25(2):193-204.

PMID: 39864046 DOI: 10.1007/s12012-024-09958-y.

NADPH oxidase 2 mediates cardiac sympathetic denervation and myocyte autophagy, resulting in cardiac atrophy and dysfunction in doxorubicin-induced cardiomyopathy.

Ma Y, Zhao H, Yang L, Li L, Wang A, Zhang X Sci Rep. 2024; 14(1):6971.

PMID: 38521855 PMC: 10960835. DOI: 10.1038/s41598-024-57090-2.

Characterization of anthracycline-induced cardiotoxicity by diffusion tensor magnetic resonance imaging.

Lohr D, Thiele A, Stahnke M, Braun V, Klopfleisch R, Klein O Basic Res Cardiol. 2024; 120(1):57-69.

PMID: 38483601 PMC: 11790774. DOI: 10.1007/s00395-024-01039-z.

Novel Transcriptomic Interactomes of Noncoding RNAs in the Heart under Altered Thyroid Hormonal States.

Rajagopalan V, Chakraborty S, Lin R Int J Mol Sci. 2023; 24(7).

PMID: 37047531 PMC: 10095585. DOI: 10.3390/ijms24076560.

Does Myocardial Atrophy Represent Anti-Arrhythmic Phenotype?.

Szeiffova Bacova B, Andelova K, Sykora M, Benova T, Barancik M, Kurahara L Biomedicines. 2022; 10(11).

PMID: 36359339 PMC: 9687767. DOI: 10.3390/biomedicines10112819.

References

Zhang S, Liu X, Bawa-Khalfe T, Lu L, Lyu Y, Liu L . Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18(11):1639-42. DOI: 10.1038/nm.2919. View

von Haehling S, Anker S . Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2011; 1(1):1-5. PMC: 3060651. DOI: 10.1007/s13539-010-0002-6. View

Campos E, OConnell J, Malvestio L, Romano M, Ramos S, Celes M . Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. Eur J Pharmacol. 2011; 670(2-3):541-53. DOI: 10.1016/j.ejphar.2011.09.021. View

Murphy K . The pathogenesis and treatment of cardiac atrophy in cancer cachexia. Am J Physiol Heart Circ Physiol. 2016; 310(4):H466-77. DOI: 10.1152/ajpheart.00720.2015. View

Tian M, Asp M, Nishijima Y, Belury M . Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol. 2011; 39(5):1321-6. DOI: 10.3892/ijo.2011.1150. View

Neilan T, Coelho-Filho O, Pena-Herrera D, Shah R, Jerosch-Herold M, Francis S . Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol. 2012; 110(11):1679-86. PMC: 3496816. DOI: 10.1016/j.amjcard.2012.07.040. View

Speyer J, Green M, Zeleniuch-Jacquotte A, Wernz J, Rey M, Sanger J . ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992; 10(1):117-27. DOI: 10.1200/JCO.1992.10.1.117. View

Thavendiranathan P, Wintersperger B, Flamm S, Marwick T . Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013; 6(6):1080-91. DOI: 10.1161/CIRCIMAGING.113.000899. View

Poterucha J, Kutty S, Lindquist R, Li L, Eidem B . Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. J Am Soc Echocardiogr. 2012; 25(7):733-40. DOI: 10.1016/j.echo.2012.04.007. View

10.

Bristow M, Mason J, Billingham M, Daniels J . Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981; 102(4):709-18. DOI: 10.1016/0002-8703(81)90096-x. View

11.

Poulin F, Thavendiranathan P . Cardiotoxicity due to chemotherapy: role of cardiac imaging. Curr Cardiol Rep. 2015; 17(3):564. DOI: 10.1007/s11886-015-0564-1. View

12.

Burridge P, Holmstrom A, Wu J . Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. Curr Protoc Hum Genet. 2015; 87:21.3.1-21.3.15. PMC: 4597313. DOI: 10.1002/0471142905.hg2103s87. View

13.

Jordan J, Vasu S, Morgan T, DAgostino Jr R, Melendez G, Hamilton C . Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors. Circ Cardiovasc Imaging. 2016; 9(8). PMC: 5508215. DOI: 10.1161/CIRCIMAGING.115.004325. View

14.

Ghigo A, Li M, Hirsch E . New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta. 2016; 1863(7 Pt B):1916-25. DOI: 10.1016/j.bbamcr.2016.01.021. View

15.

Wang X, Wang X, Chen H, Wu D, Chen J, Wang X . Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem Pharmacol. 2014; 88(3):334-50. DOI: 10.1016/j.bcp.2014.01.040. View

16.

Octavia Y, Tocchetti C, Gabrielson K, Janssens S, Crijns H, Moens A . Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012; 52(6):1213-25. DOI: 10.1016/j.yjmcc.2012.03.006. View

17.

Manne N, Lima M, Enos R, Wehner P, Carson J, Blough E . Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin/+ mouse. Int J Oncol. 2013; 42(6):2134-40. PMC: 3699594. DOI: 10.3892/ijo.2013.1893. View

18.

Musolino V, Palus S, Tschirner A, Drescher C, Gliozzi M, Carresi C . Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation. J Cachexia Sarcopenia Muscle. 2016; 7(5):555-566. PMC: 4864048. DOI: 10.1002/jcsm.12116. View

19.

Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M . Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling. Circ Heart Fail. 2014; 8(1):98-108. DOI: 10.1161/CIRCHEARTFAILURE.114.001180. View

20.

Min K, Kwon O, Smuder A, Wiggs M, Sollanek K, Christou D . Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy. J Physiol. 2015; 593(8):2017-36. PMC: 4405757. DOI: 10.1113/jphysiol.2014.286518. View